{"name":"Eyenuk","domain":"eyenuk.com","url":"https://optimly.ai/brand/eyenuk","is_claimed":false,"categories":["ai-machine-learning","healthcare-it"],"headers":[{"header":"Overview","sections":[{"key":"short_description","label":"Tagline","shape":"text","content":"Eyenuk's EyeArt is the first and only FDA 510(k)-cleared autonomous AI for simultaneous detection of mtmDR and vtDR, boasting high accuracy (96% sensitivity, 88% specificity for mtmDR; 97% sensitivity, 90% specificity for vtDR). It's a multidisease platform expanding to detect AMD, glaucoma, and predictive biomarkers, is compatible with multiple retinal camera models, and operates without typically needing patient dilation.","source_type":"1p_website","source_label":"Brand's website","source_url":"https://eyenuk.com","updated_at":"2026-10-04T00:07:53.310000+00:00"},{"key":"description","label":"Description","shape":"text","content":"Eyenuk provides the first and only FDA 510(k)-cleared autonomous AI (powered by EyeArt) that detects vision-threatening diabetic retinopathy. The solution offers immediate health insights through non-invasive retinal imaging, designed for early detection, triage, and monitoring of eye diseases like DR, AMD, and glaucomatous signs without requiring specialists for initial screening.","source_type":"1p_website","source_label":"Brand's website","source_url":"https://eyenuk.com","updated_at":"2026-10-04T00:07:53.310000+00:00"}]},{"header":"Offerings","sections":[{"key":"core_capabilities","label":"Core capabilities","shape":"text","content":"EyeArt\nan autonomous AI system for retinal screening that detects more than mild and vision-threatening diabetic retinopathy (mtmDR/vtDR)\nAge-related Macular Degeneration (AMD)\nand glaucomatous signs.","source_type":"1p_website","source_label":"Brand's website","source_url":"https://eyenuk.com","updated_at":"2026-10-04T00:07:53.310000+00:00"},{"key":"pricing","label":"Pricing","shape":"text","content":"The system enables healthcare providers to generate immediate revenue by billing CPT 92229 for autonomous, specialist-free AI retinal screening, aligning with value-based care models.","source_type":"1p_website","source_label":"Brand's website","source_url":"https://eyenuk.com","updated_at":"2026-10-04T00:07:53.310000+00:00"}]},{"header":"Audience","sections":[{"key":"target_industry","label":"Target industry","shape":"text","content":"Healthcare providers including primary care, endocrinology, optometry, ophthalmology, and large public health screening programs. It serves clinical settings in the US and globally.","source_type":"1p_website","source_label":"Brand's website","source_url":"https://eyenuk.com","updated_at":"2026-10-04T00:07:53.310000+00:00"}]}],"last_refreshed_at":"2026-10-04T00:07:53.310000+00:00","last_changed_at":"2026-10-17T23:48:15.488677+00:00","claim_url":"https://app.optimly.ai/sign-up?claim=ff9ff7d5-2c2b-44d7-a71c-d9f8fd560d7c"}